Brief: Invo Bioscience Regains Full U.S. Commercialization Rights To Its Invocell Technology
03/02/2022 15:44
Feb 3 (Reuters) -
* INVO BIOSCIENCE INC - EFFECTIVE FEBRUARY 1, 2022, INVO
REGAINED
FULL U.S. COMMERCIALIZATION RIGHTS TO ITS INVOCELL TECHNOLOGY
Source text for Eikon: ID:nPn28Dpmja
((Reuters.Briefs@thomsonreuters.com;))
Recent news on INVO Fertility
See all newsINVO Fertility Q2 revenue rises, partly on acquisitions
Invo Fertility Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Invo Fertility Inc Expected To Post A Loss Of 70 Cents A Share: Earnings Preview
Brief: INVO Fertility - Entered Into Any Market Purchase Agreement With Alumni Capital Lp
Invo Fertility Inc Reports Results For The Quarter Ended March 31: Earnings Summary